Preclinical Product Articles & Analysis
17 news found
Ace Therapeutics, a leading provider of preclinical research services and products, is proud to announce the launch of its extensive suite of diabetic mouse models. These models have been specifically designed to enable research on different types of diabetes including type 1, type 2, and gestational diabetes, providing valuable insights into disease mechanisms and potential treatment options. ...
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its comprehensive portfolio of ELISA Based Assays for vaccine development and bioprocess applications. Vaccine development involves a variety of assays to support vaccine research and development, from early preclinical studies to final production, quality ...
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, is pleased to announce the appointment of Filippo Mulinacci, Ph.D., MBA as chief business officer. “We are thrilled to welcome Filippo to our executive team,” said Philipp Spycher, Ph.D., chief executive officer of Araris Biotech. “Filippo’s extensive experience in ...
Formulation development is of paramount importance for new drug development as it can determine patentability, lifecycle and, ultimately, the success of a pharmaceutical product. Fully aware of the challenges that may arise from this process, CD Formulation recently announces that it now provides a comprehensive range of formulation development and analytical services for the pharmaceutical ...
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today that data related to REL-1017, the company's lead product candidate, will be presented in two poster presentations and one oral presentation at the Ketamine & Related Compounds International Hybrid Conference 2022. The conference is being held ...
Elizabeth Tarka, M.D. appointed Chief Medical Officer A. Brian Davis named Chief Financial Officer XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced that it has appointed Elizabeth Tarka, M.D. as Chief Medical Officer and A. Brian Davis as Chief Financial Officer. These experienced pharmaceutical ...
Expect to close our follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depositary Shares (ADSs) for gross proceeds of $27.6 million before deducting underwriter fees and commissions and other offering expenses Data reported in early July 2021 from EVX-01 Phase 1/2a clinical trial showed a robust anti-tumor effect in combination with anti-PD-1 treatment for ...
UTRECHT, The Netherlands and PHILADELPHIA, July 27, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced the appointment of Amy Garabedian as general counsel and corporate secretary. Ms. Garabedian is a seasoned leader with extensive ...
GALWAY, Ireland–(BUSINESS WIRE)–Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced expansions of its leadership team. The hires bring deep medical device industry and ear, nose and throat-specific experience to the company that will support commercial advancement of Neurent’s proprietary NEUROMARK™ ...
Abologix develops a new therapeutic option to treat lymphoma patients who have become resistant to conventional treatments. The Geneva-based biotech startup is a spin-out from the laboratories at the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG). Abologix will use the CHF 150,000 to advance the preclinical development of its product, refine its commercial and competitive ...
ByAbologix
Successfully completed initial public offering on U.S. Nasdaq in February 2021, raising gross proceeds of $30 million Clinical development on track with dosing of first patient in Phase 1/2a melanoma trial of cancer vaccine EVX-02 Cash reserves of $5.8 million at December 31, 2020 plus funds from IPO provide funding for at least 12 months from the date of completion of the IPO COPENHAGEN, ...
The development of a technology able to deliver multi-pathogen vaccine candidates against the most worrisome antibiotic-resistant bacteria has attracted new investors to Vaxdyn, the Portuguese venture capital firm Bionova Capital and the international cross-sectorial Arquimea Group. Each of the new investors has joined the capital of Vaxdyn with the acquisition of shares valued €300,000 ...
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics’ artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in four rare disease indications with high unmet need. Deep Genomics will receive an undisclosed upfront ...
Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today that Ferdinand Massari, M.D., has been appointed Chief Medical Officer. Dr. Massari is based in Boston and will oversee clinical development and contribute to expanding the company’s AI platform and therapeutic portfolio. “In a short period of time, our artificial intelligence platform has ...
CARB-X is awarding Vaxdyn, based in Seville, Spain, up to US$892,000, plus an additional $6.36 million if certain project milestones are met, to develop a new vaccine to prevent life-threatening drug-resistant infections, including pneumonia. Vaxdyn is the first Spanish biotech to be funded by CARB-X, a non-profit partnership investing $500 million in the development of innovative vaccines, ...
Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, announced today that it has received EUR 1.2 million in funding from the European Fund for Regional Development (EFRO) through the Northern Netherlands Alliance (SNN) and the city and province of Groningen, to support clinical validation of its Liver and Pancreas Sealant Patch. ...
ByRegenity
Vascuqen Inc. today announced that it has licensed a suite of intellectual property developed at the Indiana University (IU) School of Medicine related to blood vessel formation from adult stem cells. The regenerative medicine company is focused on finding therapies to repair tissues damaged by reduced blood flow due to disease or injury. The worldwide, exclusive licenses include patent rights ...